CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting programmed cell death1 (PD­1) and its ligand (PD-L1) have greatly improved therapeutic outcomes in multiple carcinomas including advanced non-small cell lung cancer (NSCLC).